FDG-PET for the evaluation of tumor viability after anticancer therapy

To evaluate positron emission tomography with18F-fluorodeoxy glucose (FDG-PET) as an diagnostic tool to determine tumor viability after anticancer therapy, fourteen patients were examined by FDG-PET after the end of the treatment. The lesions with residual viable tumor cells showed higher uptake of FDG than surrounding normal soft tissue. The lesions, in which tumor viability was lost or very low, showed higher uptake of FDG in four cases and similar uptake to normal soft tissue in three cases. The residual increased uptake of FDG was considered to be caused by remaining tumor cells and/or inflammatory reaction to anticancer treatment. FDG-PET after anticancer treatment should be interpreted by considering the reaction due to the treatment and the partial volume artifact of PET caused by the limited spatial resolution.

[1]  J. Itami,et al.  Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  C. Perez,et al.  Principles and Practice of Radiation Oncology , 1987 .

[3]  R L Wahl,et al.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1991, Radiology.

[4]  E. Hoffman,et al.  Quantitation in Positron Emission Computed Tomography: 1. Effect of Object Size , 1979, Journal of computer assisted tomography.

[5]  G van Kaick,et al.  Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  K Wienhard,et al.  Journal of Cerebral Blood Flow and Metabolism Comparative Regional Analysis of 2-fluorodeoxyglucose and Methylglucose Uptake in Brain of Four Stroke Patients. with Special Reference to the Regional Estimation of the Lumped Constant , 2022 .

[7]  G. van Kaick,et al.  PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  T Ido,et al.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  G. Chiro.  Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. , 1987 .

[10]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  K Wienhard,et al.  Estimation of Local Cerebral Glucose Utilization by Positron Emission Tomography of [18F]2-Fluoro-2-Deoxy-D-Glucose: A Critical Appraisal of Optimization Procedures , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  S. Minoshima,et al.  The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.